Table 3.

Clinical parameters and complement measures in patients treated with eculizumab and a prolonged interdose interval

No.	Coexisting condition	Variant(s)	Interdose interval, weeks	Hb, mmol/l	LDH, U/l	Platelets, ×109/L	Creatinine, μmol/l	C4, g/l	C3, g/l	CPFA, %	Ex vivo C5b9, % of the controla
M00018	None	C3, CFI	4	7.7	294	340	32	ND	ND	1	12
			6	8.2	237	299	38	0.19	1.12	2	8
M06518	Surgery	None	3	6.1	166	156	103	ND	ND	116	30
M06018	Hypertensive emergency	None	3	7.7	134	236	399	0.22	1.10	3	14
M99917	Hypertensive emergency	CFI, THBD	3	8.6	165	210	190	ND	ND	21	45
M08316	Pregnancy		4	8.7	139	204	106	0.22	0.82	1	11
			6	8.2	132	174	103	0.24	0.85	2	11
M01715	Hypertensive emergency	CFI	4	7.4	141	393	288	0.29	1.16	102	229
M04010	Hypertensive emergency	CFH	4	6.8	138	216	132	0.21	0.56	0	29

CPFA, classical pathway functional activity; Hb, hemoglobin; LDH, lactate dehydrogenase.

Case numbers are taken from the Maastricht cohort.

^aEx vivo C5b9 formation on the perturbed endothelium.